*Chief Editors*

L. L. IVERSEN (Cambridge) K. SUZUKI (Bronx, NY)

Deputy Editors

H. S. BACHELARD (London) R. MARTENSON (Bethesda, MD)
 F. FONNUM (Kjeller) W. T. NORTON (Bronx, NY)
 L. S. WOLFE (Montreal)

Editorial Board

D. H. ADAMS (Newcastle-upon-Tyne)	E. M. KREPS (Leningrad)
R. W. ALBERS (Bethesda, MD)	M. KUROKAWA (Tokyo)
M. H. APRISON (Indianapolis, IN)	M. B. LEES (Waltham, MA)
S. H. BARONDES (La Jolla, CA)	H. R. MAHLER (Bloomington, IN)
C. F. BAXTER (Sepulveda, CA)	R. M. MARCHBANKS (London)
S. BERL (New York City)	R. McCAMAN (Duarte, CA)
E. BOCK (Copenhagen)	R. MICHELL (Birmingham)
H. F. BRADFORD (London)	M. OTSUKA (Tokyo)
J.-P. CHANGEUX (Paris)	H. M. PAPIUS (Montreal)
M. CUENOD (Zurich)	J. V. PASSONNEAU (Bethesda, MD)
J. GLOWINSKI (Paris)	P. J. ROBERTS (Southampton)
A. HAMBERGER (Goteborg)	K. SANDHOFF (Munich)
B. HAMPRECHT (Martinsried)	B. K. SIESJÖ (Lund)
L. HORROCKS (Columbus, OH)	S. H. SNYDER (Baltimore, MD)
R. KATZMAN (Bronx, NY)	W. STOFFEL (Cologne)
P. M. KEEN (Bristol)	K. TIPTON (Dublin)
W. KLEE (Bethesda, MD)	R. J. WURTMAN (Cambridge, MA)

*International Society for Neurochemistry
 Publications Committee*

G. B. ANSELL (Birmingham)	P. McGEER (Vancouver, BC)
R. BALAZS (London)	E. SHOOTER (Stanford, CA)
H. C. BUNIATIAN (Yerevan)	L. SOKOLOFF (Bethesda, MD) (Chairman)
R. BURTON (St. Louis, MO)	K. SUZUKI (Bronx, NY)
L. L. IVERSEN (Cambridge)	Y. TSUKADA (Tokyo)



Published by Pergamon Press
 Oxford · New York · Paris · Frankfurt
 for
 International Society for Neurochemistry



PAR1038

IPR of U.S. Patent No. 8,772,306

Page 1 of 14

Chief Editors

- L. L. IVERSEN: *Journal of Neurochemistry, P.O. Box 98, Cambridge, CB1 2NT, U.K.*
 K. SUZUKI: *Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, U.S.A.*

Deputy Editors

- H. S. BACHELARD: *Department of Biochemistry, St. Thomas's Hospital Medical School, London SE1 7EH, U.K.*
 F. FONNUM: *Norwegian Defence Research Establishment, Division for Toxicology, P.O. Box 25-N-2007, Kjeller, Norway.*
 R. MARTENSON: *Laboratory of Cerebral Metabolism, National Institute of Mental Health, Bethesda, MD 20014, U.S.A.*
 W. T. NORTON: *Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, U.S.A.*
 L. S. WOLFE: *Montreal Neurological Institute, McGill University, 3801 University Street, Montreal 112, Quebec, Canada.*

Production Editor

- S. E. BODEN: *Journals Department, Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, U.K.*

Editorial Board

- | | | |
|--|---|--|
| D. H. ADAMS (<i>Newcastle-upon-Tyne</i>) | B. HAMPRECHT (<i>Martinsried</i>) | R. MICHELL (<i>Birmingham</i>) |
| R. W. ALBERS (<i>Bethesda, MD</i>) | L. HORROCKS (<i>Columbus, OH</i>) | M. OTSUKA (<i>Tokyo</i>) |
| M. H. APRISON (<i>Indianapolis, IN</i>) | R. KATZMAN (<i>Bronx, NY</i>) | H. M. PAPIUS (<i>Montreal</i>) |
| S. H. BARONDES (<i>La Jolla, CA</i>) | P. M. KEEN (<i>Bristol</i>) | J. V. PASSONNEAU (<i>Bethesda, MD</i>) |
| C. F. BAXTER (<i>Sepulveda, CA</i>) | W. KLEE (<i>Bethesda, MD</i>) | P. J. ROBERTS (<i>Southampton</i>) |
| S. BERL (<i>New York City</i>) | E. M. KREPS (<i>Leningrad</i>) | K. SANDHOFF (<i>Munich</i>) |
| E. BOCK (<i>Copenhagen</i>) | M. KUROKAWA (<i>Tokyo</i>) | B. K. SIESJÖ (<i>Lund</i>) |
| H. F. BRADFORD (<i>London</i>) | M. B. LEES (<i>Waltham, MA</i>) | S. H. SNYDER (<i>Baltimore, MD</i>) |
| J.-P. CHANGEUX (<i>Paris</i>) | H. R. MAHLER (<i>Bloomington, IN</i>) | W. STOFFEL (<i>Cologne</i>) |
| M. CUENOD (<i>Zurich</i>) | R. M. MARCHBANKS (<i>London</i>) | K. TIPTON (<i>Dublin</i>) |
| J. GLOWINSKI (<i>Paris</i>) | R. MCCAMAN (<i>Duarte, CA</i>) | R. J. WURTMAN (<i>Cambridge, MA</i>) |
| A. HAMBERGER (<i>Goteborg</i>) | | |

Advisory Board

- | | | |
|---|--|---|
| B. W. AGRANOFF (<i>Ann Arbor, MI</i>) | J. N. HAWTHORNE (<i>Nottingham</i>) | D. MORRIS (<i>Southampton</i>) |
| A. AMES, III (<i>Boston, MA</i>) | L. HERTZ (<i>Saskatoon</i>) | S. R. NAHORSKI (<i>Leicester</i>) |
| S. H. APPEL (<i>Houston, TX</i>) | T. C. JOHNSON (<i>Manhattan, KS</i>) | J. J. PISANO (<i>Bethesda, MD</i>) |
| G. G. ASHWELL (<i>Bethesda, MD</i>) | J. N. KANFER (<i>Winnipeg</i>) | G. PORCELLATI (<i>Perugia</i>) |
| R. BALÁZS (<i>London</i>) | S. KAUFMAN (<i>Bethesda, MD</i>) | S. PRUSINER (<i>San Francisco, CA</i>) |
| E. A. BARNARD (<i>London</i>) | K. KURIYAMA (<i>Kyoto</i>) | R. H. QUARLES (<i>Bethesda, MD</i>) |
| D. A. BOOTH (<i>Birmingham</i>) | R. LEDDEN (<i>Bronx, NY</i>) | T. RALL (<i>Charlottesville, VA</i>) |
| M. B. BORNSTEIN (<i>Bronx, NY</i>) | L. LIM (<i>London</i>) | E. DE ROBERTIS (<i>Buenos Aires</i>) |
| A. A. BOULTON (<i>Saskatoon</i>) | G. G. LUNT (<i>Bath</i>) | S. P. R. ROSE (<i>Bletchley, Bucks</i>) |
| P. R. CARNEGIE (<i>Victoria</i>) | M. H. MAKMAN (<i>Bronx, NY</i>) | M. J. SCHMIDT (<i>Indianapolis, IN</i>) |
| G. CURZON (<i>London</i>) | R. U. MARGOLIS (<i>New York, NY</i>) | G. SCHULTZ (<i>Heidelberg</i>) |
| I. DIAMOND (<i>San Francisco, CA</i>) | W. O. MCCLURE (<i>Los Angeles, CA</i>) | J. C. SCHWARTZ (<i>Paris</i>) |
| T. E. DUFFY (<i>New York, NY</i>) | B. S. MCEWEN (<i>New York City</i>) | D. F. SHARMAN (<i>Cambridge</i>) |
| Y. DUNANT (<i>Geneva</i>) | H. MCILWAIN (<i>London</i>) | M. B. SPORN (<i>Bethesda, MD</i>) |
| L. F. ENG (<i>Palo Alto, CA</i>) | G. M. MCKHANN (<i>Baltimore, MD</i>) | H. THOENEN (<i>Basel</i>) |
| H. GAINER (<i>Bethesda, MD</i>) | J. F. MEAD (<i>Los Angeles, CA</i>) | S. TUCEK (<i>Praha</i>) |
| M. HAMON (<i>Paris</i>) | P. MORELL (<i>Chapel Hill, NC</i>) | M. VOADEN (<i>London</i>) |
| G. HAUSER (<i>Belmont, MA</i>) | | N. WEINER (<i>Denver, CO</i>) |

Publishing, Subscription and Advertising Offices: Headington Hill Hall, Oxford OX3 0BW (Oxford 64881) Published monthly (Two volumes per annum). 1979 Subscription (including postage and insurance): to libraries, university departments, government laboratories, industrial and other multiple-reader institutions US \$230.00 per annum; to members of the International Society for Neurochemistry \$30.00. Airmail Subscription extra. All subscription enquiries should be addressed to The Subscription Fulfillment Manager at the above address.

Specially reduced rates to individuals: In the interests of maximizing the dissemination of the research results published in this important international journal we have established a price structure whereby any individual whose institution takes out a library subscription, may purchase a second or additional subscription for their personal use at a much reduced rate of \$75.00 per annum.

Microform Subscriptions and Back Issues: Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Copyright © 1979 International Society for Neurochemistry Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the copyright owner if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

U.S. Copyright Law applicable to Users in the U.S.A.

The Article Fee Code on the first page of an article in this journal indicates the copyright owner's consent, that in the U.S.A., copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law, is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center Inc., PO Box 765, Schenectady, NY 12301. If a code does not appear copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

PERGAMON PRESS
 HEADINGTON HILL HALL, OXFORD OX3 0BW
 MAXWELL HOUSE, FAIRVIEW PARK, ELMSFORD, NEW YORK 10523

DI-n-PROPYLACETATE AND GABA DEGRADATION. PREFERENTIAL INHIBITION OF SUCCINIC SEMIALDEHYDE DEHYDROGENASE AND INDIRECT INHIBITION OF GABA-TRANSAMINASE

J. W. VAN DER LAAN¹, TH. DE BOER² and J. BRUINVELS

Department of Pharmacology, Faculty of Medicine, Erasmus University Rotterdam,
P.O. Box 1738, 3000 DR Rotterdam, The Netherlands

(Received 21 July 1978. Revised 20 December 1978. Accepted 15 January 1979)

Abstract—The kinetic constants for 4-aminobutyrate: 2-oxoglutarate aminotransferase (GABA-transaminase) and succinate-semialdehyde: NAD⁺ oxidoreductase (SSA-DH) have been determined using rat brain homogenate.

The Michaelis constants for GABA-T at saturated substrate concentrations were calculated to be $K_{\text{GABA}} = 1.5 \text{ mM}$, $K_{2\text{-OG}} = 0.25 \text{ mM}$, $K_{\text{GLU}} = 620 \mu\text{M}$, and $K_{\text{SSA}} = 87 \mu\text{M}$. The V_{max} for the reaction using GABA and 2-oxoglutarate (2-OG) as substrates (forward reaction) was found to be $35.2 \mu\text{mol/g/h}$, whereas for the reaction using glutamate (Glu) and succinate-semialdehyde (SSA) a value of $63.0 \mu\text{mol/g/h}$ was found.

The kinetics of GABA-T have been shown to be consistent with a Ping Pong Bi Bi mechanism. Substrate inhibition of the forward reaction, through formation of a dead-end complex, was found to occur with 2-OG ($K_i = 3.3 \text{ mM}$), whereas GABA was found to be a product inhibitor of the reverse reaction ($K_i = 0.6 \text{ mM}$). Using the appropriate Haldane relationship, a K_{eq} of 0.04 for GABA-T was found, indicating that the reaction was strongly biased towards GABA.

For SSA-DH, the K_m of SSA was determined ($9.1 \mu\text{M}$) and the V_{max} was $27.5 \mu\text{mol/g/h}$. The effect of di-n-propylacetate (DPA) on both GABA-T and SSA-DH was measured. DPA inhibited SSA-DH competitively with respect to SSA, giving a K_i of 0.5 mM . GABA-T was only slightly inhibited. The K_i of DPA for the forward reaction was 23.2 mM with respect to GABA, which was 40–50 times higher than that for SSA-DH. For the reverse reaction the K_i of DPA was found to be nearly the same (15.2 mM with respect to Glu and 22.9 mM with respect to SSA). These results suggest that GABA accumulation in the brain, after administration of DPA *in vivo*, is caused by SSA-DH inhibition. Two mechanisms are indicated by the data. (1) The higher level of SSA, which results from inhibition of SSA-DH, initiates the reverse reaction of GABA-T, thus increasing the level of GABA via conversion of SSA. (2) The degradation of GABA is inhibited by SSA, since SSA has a strong inhibitory effect on the forward reaction, as calculated from the present data.

IN MAMMALIAN brain gamma-aminobutyric acid (GABA) is thought to be an inhibitory neurotransmitter (KRNJEVIĆ, 1970). A decrease in the concentration of GABA has been implicated in the onset of convulsions (TOWER, 1976). Accordingly, it has been reported by many authors that several anti-

convulsant drugs increase GABA levels in the brain through inhibition of its degradation (See TAPIA, 1975).

Elevation of GABA levels has been extensively studied by administration of drugs which affect the activity of 4-aminobutyrate: 2-oxoglutarate aminotransferase (EC 2.6.1.19; GABA-T). Such drugs include aminooxyacetic acid (AOAA; BAXTER & ROBERTS, 1961), ethanolamine-O-sulphate (EOS; FOWLER & JOHN, 1972), γ -acetylene-GABA and γ -vinyl-GABA (SCHECHTER *et al.*, 1977; JUNG *et al.*, 1977). Similarly, di-n-propylacetate (Depakine®, Valproate, DPA) also increases the concentration of GABA in the brain (ANLEZARK *et al.*, 1976; GODIN *et al.*, 1969; SIMLER *et al.*, 1973) and its action has been ascribed to an inhibition of GABA-T (GODIN *et al.*, 1969; SIMLER *et al.*, 1973; FOWLER *et al.*, 1975). However, some authors reported a preferential action of DPA on SSA-DH (HARVEY *et al.*, 1975; ANLEZARK *et al.*, 1976). Two specific reactions are involved in

¹ To whom correspondence should be addressed.

² Present address: Department of Pharmacology, Faculty of Medicine, Free University, Van de Boechorsstr. 7, 1081 BT Amsterdam, The Netherlands.

Abbreviations used: GABA-T, 4-aminobutyrate: 2-oxoglutarate aminotransferase (EC 2.6.1.19); SSA-DH, succinate-semialdehyde: NAD(P)⁺ oxidoreductase (EC 1.2.1.16); Glu, glutamate; SSA, succinate-semialdehyde; 2-OG, 2-oxoglutarate; SA, succinate; DPA, di-n-propylacetate; K , Michaelis constant under saturated conditions; K_m , apparent Michaelis constant under non-saturated conditions; V , maximum velocity under saturated conditions; V_{max} , apparent maximum velocity at a fixed non-saturating concentration of a single substrate.

the degradation of GABA; firstly, the reversible conversion of GABA and 2-oxoglutarate (2-OG) into succinate-semialdehyde (SSA) and glutamate (Glu), respectively, which is catalysed by GABA-T, and secondly, the subsequent oxidation of SSA to form succinate by succinate-semialdehyde: NAD⁺ oxidoreductase (EC 1.2.1.16; SSA-DH) using NAD as a cofactor, which reaction is almost irreversible. Since the equilibrium of the GABA-T catalysed reaction is biased towards GABA (DUFFY *et al.*, 1972), inhibition of SSA-DH may also result in elevation of the GABA concentration. However, this possibility has so far been neglected, because SSA-DH was considered to be very efficient in preventing accumulation of SSA. Recent studies have suggested that the activity of SSA-DH can be affected by mono- and bivalent cations like sodium, potassium and calcium (DE BOER & BRUINVELS, 1977b). Therefore, it is possible that SSA-DH may play a regulating role in GABA degradation *in vivo* and that inhibition of this enzyme might increase GABA concentrations through activating the reverse reaction of GABA-T.

The aim of the present paper has, therefore, been to study this regulatory role of SSA-DH in relation to the action of DPA. The affinity of SSA for both GABA-T and SSA-DH and its alteration by DPA have been determined as well as the effect of DPA on the conversion of GABA into SSA.

MATERIALS AND METHODS

Materials. GABA was obtained from Calbiochem, Los Angeles, CA. Triton X-100, 2-oxoglutaric acid, di-sodium succinate and 2-mercaptoethanol were obtained from BDH Chemicals Ltd. Pyridoxamine-di-HCl and SSA were purchased from Sigma Chemical Company. NAD and NADH were obtained from Boehringer-Mannheim. [¹⁴C]GABA (specific radioactivity 4.6 mCi/mmol) was obtained from the Radiochemical Centre, Amersham, U.K. All other chemicals were purchased from Merck, Darmstadt. DPA was a gift of Labaz B.V., Maassluis, The Netherlands.

Tissue preparation. Randomly selected male Wistar rats (125–175 g) were killed by decapitation and their brains were rapidly removed and weighed. A 10% (w/v) brain homogenate was prepared in an ice-cold solution containing 0.32 M-sucrose and 4.5 mM-2-mercaptoethanol, using a Teflon-glass Potter-Elvehjem homogenizer. One volume of the homogenate was added to 3 vol of ice-cold Triton medium (0.67% w/v Triton X-100, 50 mM-Tris-HCl (pH 8.5) and 4.5 mM-2-mercaptoethanol) and kept on ice-water for 1 h before use.

GABA-T assay using GABA as substrate (forward reaction). For the performance of the assay of the GABA-T forward reaction a radiochemical method was used as previously described (DE BOER & BRUINVELS, 1977a) with the following modifications. NAD was omitted from the incubation mixture, unless otherwise specified, to exclude interference with SSA-DH, since DPA might affect this enzyme too. A control was carried throughout the whole procedure in the presence of NAD but without DPA. Tissue concentration was 4.44 mg/ml (wet wt.). After precubation at 22°C for 30 min the reaction was started by the addition of homogenate and the mixture was incubated for a further

30 min at the same bath temperature. All experiments were carried out in duplicate.

GABA-T assay using SSA as substrate (reverse reaction). The reaction was carried out under similar conditions to the forward reaction. The incubation mixture contained 50 mM-Tris-HCl (pH 8.5), 20 mM-2-mercaptoethanol and 0.12 ml Triton-treated homogenate in a total volume of 0.615 ml. The final tissue concentration was 4.44 mg/ml. The reaction mixture was preincubated at 22°C for 1 h in the presence of glutamate (0.5–5.0 mM) and in the absence of SSA. The reaction was started by addition of 60 μl SSA solution, resulting in final concentrations of 50–600 μM-SSA. For the inhibition studies DPA was added simultaneously with SSA.

Since the sodium salt of DPA was used throughout this study, a solution in which DPA was replaced by sodium-isethionate, equimolar to the highest DPA concentration, was used as control.

After an incubation period of 15 or 20 min, the reaction was terminated by adding an equal volume of ice-cold 5% TCA solution. Subsequently, the tubes were placed in ice-water. After centrifugation (10 min × 1200 g) the concentration of 2-OG in 0.5 ml of the supernatant was determined in duplicate.

Determination of 2-oxoglutarate. The fluorometric determination of α-oxo acids as described by TAKEDA *et al.* (1976) was used. To neutralize 0.5 ml of the 2.5% TCA solution (sample solution), 0.2 ml of a solution containing 2 vol 1 M-Tris-HCl (pH 8.3) and 1 vol 1 M-NaOH was added. Thereafter, 5 ml of a solution containing 2% (v/v) pyridine in methanol, 100 mg/l pyridoxamine-di-HCl and 2.0 g/l zinc acetate was added. The reaction of pyridoxamine, 2-oxoglutarate and Zn(II) ion was found to yield a Zn(II) chelate of the aldimine (MATSUSHIMA & MARTELL, 1967). After incubation for 30 min at 37°C the reaction mixture was cooled in ice-water for 3–5 min. The fluorescence intensity was measured within 2 h at room temperature using a Baird-Atomic spectrophotofluorometer with excitation at 395 nm and emission at 475 nm. Standards and blanks were carried throughout the entire assay procedure. Blanks contained the complete incubation mixture, except SSA. The standards were prepared in the same way as blanks and 2-OG was added to final concentrations of 20–80 μM. The change in the glutamate concentration used in the GABA-T assay resulted in blanks which varied to a maximum of 20% and this variation was proportional to the glutamate concentration. Therefore, the assay was always performed with standards of all glutamate concentrations used. Incubation mixtures, to which the TCA solution was added immediately after starting the reaction by addition of SSA, were used as additional controls. When 2-OG was incubated under the conditions of the assay in the absence of SSA it was not significantly metabolized, as measured after 1 h (recovery 98.4 ± 1.3%; n = 13).

SSA-DH assay. Measurement of the SSA-DH activity was performed as described previously (DE BOER & BRUINVELS, 1977a), using a tissue concentration of 0.44 mg/ml (wet wt.).

Data analysis. The apparent kinetic parameters of the forward reaction of GABA-T were calculated from Lineweaver-Burk plots.

Since in both the assay of the reverse reaction of GABA-T and in the assay of SSA-DH more than 5% of the initial concentration of SSA was converted, the apparent kinetic constants were calculated using the integrated form of the Henri-Michaelis-Menten equation (SEGEL, 1975).




FIG. 1. The kinetic constants of the GABA-T forward reaction. Incubations were performed in 50 mM-Tris-HCl (pH 8.5)-20 mM-2-mercaptoethanol and in the presence of Triton X-100 at a temperature of 22°C. A and D are Lineweaver-Burk plots, of the mean of three experiments, whereas B, C, E and F are replots of the reciprocal apparent kinetic constants obtained from A and D to calculate the limiting Michaelis constants. The reciprocal fixed substrate concentration is given on the horizontal axis. The equations which were applied to calculate the constants are given in the legend to Table 1. The resulting values are summarized in Table 1. A. Reciprocal plot of the velocity vs the concentration of 2-OG with GABA as a fixed substrate. GABA concentrations: ○—○, 0.5 mM; ●—●, 1.0 mM; □—□, 2.0 mM; ■—■, 5.0 mM. B. Replot of reciprocal apparent maximum velocity vs the reciprocal GABA concentration. C. Replot of the reciprocal apparent K_m for 2-OG vs the reciprocal GABA concentration. D. Reciprocal plot of the velocity vs the concentration of GABA with 2-OG as fixed substrate. 2-OG concentrations: ○—○, 0.05 mM; ●—●, 0.1 mM; □—□, 0.2 mM; ■—■, 0.5 mM; △—△, 6.0 mM. The broken line for 6.0 mM-2-OG indicates that substrate inhibition occurred. For reasons of simplicity the curves obtained with 2-OG concentrations of 1.0 mM and 2.0 mM are not shown in the figure. E. Replot of the reciprocal apparent maximum velocity vs the reciprocal 2-OG concentration. F. Replot of the reciprocal apparent K_m for GABA vs the reciprocal 2-OG concentration.

To obtain limiting Michaelis constants for the substrates of GABA-T from the apparent constants the equations for a Ping Pong Bi Bi mechanism (CLELAND, 1963) were applied, since it is generally accepted that transaminations occur via such a mechanism (MEISTER, 1955; SCOTT & JAKOBY, 1959; HENSON & CLELAND, 1964).

The type of inhibition by DPA of GABA-T was determined graphically. The K_i 's were calculated from a replot of the ratio of the apparent K_m and V_{max} vs concentration of inhibitor as suggested by SEGEL (1975) for mixed-type inhibition.

All constants were calculated from the plots using the least squares method. Variance analysis for regression lines was used to test the significance of differences in K_m and V_{max} .

RESULTS

Kinetics of GABA-T

Reaction with GABA as substrate (forward reaction). The kinetic constants of the GABA-T forward reaction were determined using concentrations of 0.5–5.0

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.